In conclusion, our case highlighted that severe intrahepatic cholestasis associated with dacomitinib hepatotoxicity warranted more awareness, and drug interactions should be monitored, especially liver metabolic enzymes CYP2D6 were involved. This evidence concerns the gene CYP2D6 and intrahepatic cholestasis.